X
SUPN icon

Xponance’s Supernus Pharmaceuticals SUPN Stock Holding History

Xponance’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$272K Sell
5,261
-605
-10% -$30.8K ﹤0.01% 1328
2025
Q4 		$292K Sell
5,866
-4
-0.1% -$194 ﹤0.01% 1198
2025
Q3 		$281K Buy
+5,870
New +$236K ﹤0.01% 1195

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Xponance's SUPN Position: Q1 2026 in Review

Xponance reduced its Supernus Pharmaceuticals (SUPN) stake by 10% in Q1 2026, selling an estimated $30.8K and leaving 5,261 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #1328.

Xponance first reported a position in SUPN in Q3 2025 and has held it in 3 quarters since. The position peaked at $292K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Xponance held 5,261 shares of Supernus Pharmaceuticals worth $272K as of Q1 2026.
  • Xponance sold 605 Supernus Pharmaceuticals shares in Q1 2026, an estimated $30.8K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1328 holding.
  • Xponance first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Xponance's Supernus Pharmaceuticals position peaked at $292K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.